173 related articles for article (PubMed ID: 36071289)
1. The effect of ciprofloxacin on doxorubicin cytotoxic activity in the acquired resistance to doxorubicin in DU145 prostate carcinoma cells.
Davary Avareshk A; Jalal R; Gholami J
Med Oncol; 2022 Sep; 39(12):194. PubMed ID: 36071289
[TBL] [Abstract][Full Text] [Related]
2. Doxorubicin Conjugated to Immunomodulatory Anticancer Lactoferrin Displays Improved Cytotoxicity Overcoming Prostate Cancer Chemo resistance and Inhibits Tumour Development in TRAMP Mice.
Shankaranarayanan JS; Kanwar JR; Al-Juhaishi AJ; Kanwar RK
Sci Rep; 2016 Aug; 6():32062. PubMed ID: 27576789
[TBL] [Abstract][Full Text] [Related]
3. Zinc oxide nanofluids: The influence of modality combinations on prostate cancer DU145 cells.
Azhdari A; Jalal R
J Cancer Res Ther; 2021; 17(2):393-400. PubMed ID: 34121683
[TBL] [Abstract][Full Text] [Related]
4. Concentration-Dependent Dual Effects of Ciprofloxacin on SB-590885-Resistant BRAF
Aldaghi SA; Jalal R
Chem Res Toxicol; 2019 Apr; 32(4):645-658. PubMed ID: 30829029
[TBL] [Abstract][Full Text] [Related]
5. Pleiotropic effects of probenecid on three-dimensional cultures of prostate cancer cells.
Uwada J; Mukai S; Terada N; Nakazawa H; Islam MS; Nagai T; Fujii M; Yamasaki K; Taniguchi T; Kamoto T; Yazawa T
Life Sci; 2021 Aug; 278():119554. PubMed ID: 33932444
[TBL] [Abstract][Full Text] [Related]
6. Combination prostate cancer therapy: Prostate-specific membranes antigen targeted, pH-sensitive nanoparticles loaded with doxorubicin and tanshinone.
Sun G; Sun K; Sun J
Drug Deliv; 2021 Dec; 28(1):1132-1140. PubMed ID: 34121558
[TBL] [Abstract][Full Text] [Related]
7. Mitochondrial delivery of doxorubicin by triphenylphosphonium-functionalized hyperbranched nanocarriers results in rapid and severe cytotoxicity.
Theodossiou TA; Sideratou Z; Katsarou ME; Tsiourvas D
Pharm Res; 2013 Nov; 30(11):2832-42. PubMed ID: 23921486
[TBL] [Abstract][Full Text] [Related]
8. Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth Inhibition, G2-M arrest, and apoptosis.
Tyagi AK; Singh RP; Agarwal C; Chan DC; Agarwal R
Clin Cancer Res; 2002 Nov; 8(11):3512-9. PubMed ID: 12429642
[TBL] [Abstract][Full Text] [Related]
9. Sildenafil increases chemotherapeutic efficacy of doxorubicin in prostate cancer and ameliorates cardiac dysfunction.
Das A; Durrant D; Mitchell C; Mayton E; Hoke NN; Salloum FN; Park MA; Qureshi I; Lee R; Dent P; Kukreja RC
Proc Natl Acad Sci U S A; 2010 Oct; 107(42):18202-7. PubMed ID: 20884855
[TBL] [Abstract][Full Text] [Related]
10. Increased anti-tumour effects of doxorubicin and zoledronic acid in prostate cancer cells in vitro: supporting the benefits of combination therapy.
Clyburn RD; Reid P; Evans CA; Lefley DV; Holen I
Cancer Chemother Pharmacol; 2010 Apr; 65(5):969-78. PubMed ID: 19730863
[TBL] [Abstract][Full Text] [Related]
11. Poly-L-arginine: Enhancing Cytotoxicity and Cellular Uptake of Doxorubicin and Necrotic Cell Death.
Movafegh B; Jalal R; Mohammadi Z; Aldaghi SA
Anticancer Agents Med Chem; 2018; 18(10):1448-1456. PubMed ID: 29651964
[TBL] [Abstract][Full Text] [Related]
12. The antioxidant phenylaminoethyl selenide reduces doxorubicin-induced cardiotoxicity in a xenograft model of human prostate cancer.
Kang JY; Costyn LJ; Nagy T; Cowan EA; Oldham CD; May SW; Arnold RD
Arch Biochem Biophys; 2011 Nov; 515(1-2):112-9. PubMed ID: 21906582
[TBL] [Abstract][Full Text] [Related]
13. Antiproliferative Activity of 8-methoxy Ciprofloxacin-Hydrozone/Acylhydrazone Scaffolds.
Wang LP; Xu Z; Deng GY; Xu SL
Curr Top Med Chem; 2020; 20(21):1911-1915. PubMed ID: 32493190
[TBL] [Abstract][Full Text] [Related]
14. Quantitative study of focused ultrasound enhanced doxorubicin delivery to prostate tumor in vivo with MRI guidance.
Chen X; Cvetkovic D; Ma CM; Chen L
Med Phys; 2012 May; 39(5):2780-6. PubMed ID: 22559650
[TBL] [Abstract][Full Text] [Related]
15. Ciprofloxacin sensitizes hormone-refractory prostate cancer cell lines to doxorubicin and docetaxel treatment on a schedule-dependent manner.
Pinto AC; Moreira JN; Simões S
Cancer Chemother Pharmacol; 2009 Aug; 64(3):445-54. PubMed ID: 19104815
[TBL] [Abstract][Full Text] [Related]
16. Cationic poly-L-lysine dendrimer complexes doxorubicin and delays tumor growth in vitro and in vivo.
Al-Jamal KT; Al-Jamal WT; Wang JT; Rubio N; Buddle J; Gathercole D; Zloh M; Kostarelos K
ACS Nano; 2013 Mar; 7(3):1905-17. PubMed ID: 23527750
[TBL] [Abstract][Full Text] [Related]
17. Doxorubicin induces prostate cancer drug resistance by upregulation of ABCG4 through GSH depletion and CREB activation: Relevance of statins in chemosensitization.
Mallappa S; Neeli PK; Karnewar S; Kotamraju S
Mol Carcinog; 2019 Jul; 58(7):1118-1133. PubMed ID: 30834613
[TBL] [Abstract][Full Text] [Related]
18. Overcoming TRAIL-resistance by sensitizing prostate cancer 3D spheroids with taxanes.
Grayson KA; Jyotsana N; Ortiz-Otero N; King MR
PLoS One; 2021; 16(3):e0246733. PubMed ID: 33661931
[TBL] [Abstract][Full Text] [Related]
19. Enhanced in vitro cytotoxicity of idarubicin compared to epirubicin and doxorubicin in rat prostate carcinoma cells.
Siegsmund MJ; Stendler A; Kreukler C; Köhrmann KU; Alken P
Eur Urol; 1997; 31(3):365-70. PubMed ID: 9129933
[TBL] [Abstract][Full Text] [Related]
20. Combination effects of docetaxel and Doxorubicin in hormone-refractory prostate cancer cells.
Tsakalozou E; Eckman AM; Bae Y
Biochem Res Int; 2012; 2012():832059. PubMed ID: 22811914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
